Related Content

Learn more about the patterns, symptoms, diagnosis and treatments available for Central Nervous System problems in DM2.

Learn more about the patterns, symptoms, diagnosis and treatments available for Central Nervous System problems in DM1.

What is the relationship between sleep apnea and DM? Modafinil is the choice although it is expensive. Sleep apnea contributes to the daytime somnolence but patients often continue to have daytime sleepiness after CPAP.

For information on how DM affects executive function, see the Body Systems Tool.

Myotonic Dystrophy News

May 14, 2021

Dr. Richard Moxley, Emeritus Member of the MDF Scientific Advisory Committee

MDF is proud to recognize Richard T. Moxley, III, MD for his distinguished service in the field of myotonic dystrophy and his role on the MDF Scientific Advisory Committee. This month Dr. Moxley is retiring from MDF’s Scientific Advisory Committee (SAC), after supporting MDF since our inception, and will now serve as an Emeritus member.

May 14, 2021

Research Fellow Feature: Maya Gosztyla

MDF is proud to announce Maya Gosztyla as one of the MDF’s 2021 Fellowship Recipients! Maya Gosztyla’s project “Investigating RNA-binding Proteins and RNA Localization in cDM1 Organoids” plans to search for new RBPs, beyond those currently known, that are dysregulated in DM1. They will conduct this analysis using cerebral organoids, which mimic the cells and structure of the human brain using spherical clumps of cells grown in a dish.

May 14, 2021

Meet Kate Beck, Special Projects Manager

MDF is excited to formally welcome Kate Beck as our Special Projects Manager! Kate first engaged with the foundation in 2019 after her close friends were diagnosed with DM. After learning more about our mission, she was inspired to help advance care and a cure.

May 14, 2021

Building on Our Rare Disease Day Success - Advocating for Increased Myotonic Dystrophy Research

MDF advocates from across the country did their part as part of another highly successful annual Rare Disease Day celebration. There has been a lot of activity in Washington, D.C. to report on since Rare Disease Day. There are also opportunities to continue our research advocacy.

May 14, 2021

Participate in a DM1 Interview Study

Your voice matters in bringing forth meaningful treatments for myotonic dystrophy. An important part of the drug development process is understanding what matters to you in potential treatment effects for new medicines.

Search form

Related Content